NOTA.F Novartis AG

Healthcare Pharmaceuticals Frankfurt Exchange
144.00 EUR
Close of Nov 13, 2026
102.24 146.00
Market cap
EUR 272B
P/E
31.9x
P/B
8.10x
ROE
27.3%
Dividend yield
2.90%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NOTA.F undervalued?

Graham number

The Graham number of Novartis AG cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Novartis AG fundamental analysis

No fundamental analysis for Novartis AG yet.

Novartis AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade fo…

Full company profile